| Literature DB >> 22566984 |
A C Laska1, T Kahan, A Hellblom, V Murray, M von Arbin.
Abstract
BACKGROUND: Aphasia affects one third of acute stroke patients. There is a considerable spontaneous recovery in aphasia, but impaired communication ability remains a great problem. Communication difficulties are an impediment to rehabilitation. Early treatment of the language deficits leading to increased communication ability would improve rehabilitation. The aim of this study is to elucidate the efficacy of very early speech and language therapy (SLT) in acute stroke patients with aphasia.Entities:
Keywords: Acute stroke; Aphasia; Language Enrichment Therapy; Speech and language therapy
Year: 2011 PMID: 22566984 PMCID: PMC3343759 DOI: 10.1159/000329835
Source DB: PubMed Journal: Cerebrovasc Dis Extra ISSN: 1664-5456
Baseline characteristics
| Training (n = 62) | Control (n = 61) | |
|---|---|---|
| Age, years (range) | 76 (38–94) | 79 (39–94) |
| Male gender, n (%) | 33 (58) | 23 (41) |
| Living alone, n (%) | 28 (46) | 29 (48) |
| Education >12 years, n (%) | 21 (42) | 20 (37) |
| Delay to inclusion, days | 3 (2–4) | 3 (2–4) |
| Stratification group, n | ||
| NIHSS<10 | 34 | 33 |
| NIHSS 11–19 | 13 | 13 |
| NIHSS >20 | 15 | 15 |
| NIHSS points | 9 (4–19) | 8 (5–19) |
| ADL index points | 25 (5–85) | 45 (5–85) |
| TOAST stroke types, n | ||
| Large vessel | 9 | 14 |
| Cardiac embolic | 26 | 26 |
| Unknown | 27 | 21 |
| OCSP stroke types, n | ||
| TACI | 7 | 10 |
| PACI | 55 | 51 |
| ANELT | 1 (0–1.4) | 1 (0–1.4) |
| Coeff | 10.5 (4–33) | 13 (4–33) |
| Fluency | 31 (1.5–47) | 33 (1.5–49) |
| Comprehension | 10 (4–22) | 9 (4–20) |
| Repetition | 1 (0–11) | 0 (0–7) |
| Naming | 0 (0–5) | 0 (0–7) |
| Atrial fibrillation, n (%) | 26 (41) | 25 (41) |
| Hypertension, n (%) | 35 (56) | 33 (54) |
| Congestive heart failure, n (%) | 8 (13) | 11 (18) |
| History of myocardial infarction, n (%) | 14 (23) | 3 (5) |
| Angina pectoris, n (%) | 10 (16) | 9 (15) |
| Hyperlipidemia, n (%) | 37 (69) | 27 (50) |
| Current smoker, n (%) | 15 (25) | 8 (13) |
| Peripherial artery disease, n (%) | 2 (3) | 1 (2) |
| Diabetes mellitus, n (%) | 9 (15) | 7 (11) |
| Carotic stenosis (>50%), n (%) | 5 (15) | 7 (18) |
| Systolic blood pressure, mm Hg | 143 (130–160) | 150 (140–165) |
| Diastolic blood pressure, mm Hg | 80 (74–86) | 80 (70–85) |
| Heart rate, beats/min | 76 (64–85) | 76 (64–80) |
| Blood glucose, mmol/l | 6.6 (5.8–7.3) | 6.4 (5.8–7.3) |
| S-creatinine, (μmol/1 | 86 (74–100) | 88 (77–107) |
| Total cholesterol, mmol/l | 4.9 (4.1–5.8) | 4.8 (4.1–5.3) |
| LDL-cholesterol, mmol/l | 3.1 (2.4–3.9) | 2.8 (2.3–3.4) |
| C-reactive protein, mg/1 | 6 (4–18) | 9 (4–15) |
Data are presented as median values and quartiles, if not otherwise stated. ADL = Activities of Daily Living, Barthel Index; TOAST = Trial of Org 10172 in Acute Stroke Treatment [18]; OCSP = Oxfordshire Community Stroke Project [19]; TACI = total anterior circulation infarct; PACI = partial anterior circulation infarct; LDL = low density lipoprotein.
Fig. 1Flow chart for randomized patients.
Primary and secondary outcomes
| Training group | Control group | p value | |
|---|---|---|---|
| Primary outcomes | |||
| ANELT by day 21, intention-to-treat, n | 59 | 55 | |
| Median | 1.3 (1–4.1) | 1.2 (0–3.6) | 0.37 |
| ANELT by day 21, per protocol, n | 54 | 49 | |
| Median | 1.5 (1–4.1) | 1.0 (0–3.6) | 0.16 |
| Secondary outcomes | |||
| Difference in coefficient at baseline and day 21, intention-to-treat, n | 58 | 56 | |
| Median | 8.5 (1–17) | 9 (3.3–16.8) | 0.86 |
| Difference in coefficient at baseline and day 21, per protocol, n | 53 | 48 | |
| Median | 9 (1.5–17.5) | 8.5 (2.3–16) | 0.62 |
| Follow-up at 6 months | |||
| ANELT, n | 50 | 49 | |
| Median | 1.8 (1–4.6) | 3 (1–4.6) | 0.49 |
| Coefficient, n | 50 | 49 | |
| Median | 40 (25–57) | 49 (17–58) | 0.62 |
Data are presented as median values and quartiles.
Fig. 2Types of aphasia at baseline. Mixed non = Mixed non-fluent, Trans mot = transcortical motor, Mixed flu = mixed fluent, Trans sens = transcortical sensory.
Effects of SLT at day 21 according to ANELT
| SLT group (n=59) | Control group (n=55) | P | |
|---|---|---|---|
| Patients with a difference in ANELT | |||
| ≥1 from baseline to day 21 | 34 responders | 19 | <0.01 |
| <1 from baseline to day 21 | 25 non-responders | 36 |